SAR445877 for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the optimal dose and assess the safety and effectiveness of SAR445877, an experimental treatment, for individuals with advanced cancers that cannot be removed or have metastasized. The study will evaluate this treatment both alone and in combination with other cancer therapies. It targets those with advanced cancers such as lung, melanoma, or colorectal cancer who lack better standard treatment options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, providing participants the opportunity to be among the first to receive this new treatment.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on ongoing corticosteroid therapy or have certain health conditions, you may not be eligible to participate. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that SAR445877 remains under evaluation for safety and effectiveness in treating advanced solid tumors. So far, studies have not provided specific details on patient tolerance. This treatment is in early testing stages, focusing on dose determination and side effect monitoring.
Regarding its combination with other drugs like ADG126, bevacizumab, and cetuximab, clear safety information for these combinations is not yet available. Researchers are studying these drugs together to assess their potential in fighting cancer more effectively.
Since SAR445877 is in early testing, scientists continue to learn about its safety in humans. This phase of research involves closely monitoring for negative effects, though specific details on these effects have not been shared.
Prospective trial participants should discuss potential risks and benefits with health professionals, who may have more detailed information.12345Why are researchers excited about this trial's treatments?
Researchers are excited about SAR445877 because it offers a fresh approach to treating advanced cancers, particularly those like non-small cell lung cancer and colorectal cancer. Unlike many current treatments that often involve chemotherapy or targeted therapies focusing on well-known cancer pathways, SAR445877 is being explored for its potential to work differently, perhaps targeting unique pathways or mechanisms within different cancer types. This could lead to more effective treatments with potentially fewer side effects. Additionally, SAR445877 is being tested both as a standalone treatment and in combination with other drugs such as ADG126, bevacizumab, and cetuximab, which could enhance its effectiveness and offer new hope for patients with these difficult-to-treat cancers.
What evidence suggests that this trial's treatments could be effective for advanced cancer?
Research shows that SAR445877, which participants in this trial may receive, has promising effects against tumors when used alone in patients with advanced solid tumors, such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Early studies found that the treatment is generally safe, and some patients experienced partial tumor shrinkage. This trial will test SAR445877 in various treatment arms, including combinations with other drugs. When combined with ADG126, SAR445877 kept CRC tumors under control for an average of 8 months, suggesting it might improve treatment outcomes. Additionally, when used with bevacizumab, SAR445877 may help better control tumors. While these findings are encouraging, more research is needed to confirm how well SAR445877 works for different types of advanced cancer.14678
Who Is on the Research Team?
Clinical Sciences & Operations
Principal Investigator
Sanofi
Are You a Good Fit for This Trial?
Adults with advanced solid tumors that can't be surgically removed or have spread, and who lack suitable standard treatments. Specific groups include those with certain types of lung, stomach, liver cancers, and gastroesophageal junction adenocarcinoma. Participants must have measurable disease and give informed consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Finding the therapeutic dose(s) of SAR445877 in monotherapy and in combination with other anticancer therapies
Dose Expansion/Optimization
Assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SAR445877
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University